

Global Health Clinics Ltd.
400-837 West Hastings Street
Vancouver, BC V6C 3N6
Tel: 1.855.537.6272

NOT FOR DISSEMINATION IN THE UNITED STATES

NEWS RELEASE

**GLOBAL HEALTH ANNOUNCES OPERATIONAL UPDATES AND PAUSE ON
PSYCHEDELIC OPERATIONS**

Vancouver, BC, December 12, 2022 – Global Health Clinics Ltd. (CSE: MJRX / FRANKFURT: L002) (“**Global Health**” or the “**Company**”) announces management and operational changes at its subsidiary, Wonder Scientific, including the Company’s decision to pause its operations related to psilocybin research.

Wonder Scientific was acquired by the Company on January 20, 2021 and was focused on sourcing and securing access to federally licensed work and bench space required for formulation and manufacturing work in the B2B sales channels of the active pharmaceutical ingredients (API) industry, including psilocybin. In order to align the strategic goals of the Company and Wonder Scientific in the biopharmaceutical industry, the Company was in discussions with Dr. Andrew Riseman, a Wonder Scientific consultant, with a view to continuing to advance the ongoing relationship between the parties towards the development of research on optimizing production for psilocybin mushrooms, mycelium productions and the creation of a genetics library. Dr. Riseman’s consulting agreement with Wonder Scientific expired at the end of May 2021 and ongoing negotiations with Dr. Riseman ended in early 2022. As a result, Dr. Riseman is no longer working with the Company and the Company is no longer pursuing access to federally licensed work and bench space with Dr. Riseman.

As announced on April 29, 2021, the Company engaged Dr. Brian Jahns, a leader in the biopharmaceutical industry to oversee the overall business development of Wonder Scientific, including its key corporate objectives of sourcing and securing access to federally licensed work and bench space. Dr. Jahns stopped working with the Company on October 2021.

In connection with the search for federally licensed work and bench space, and as announced on November 9, 2021, the Company entered into a memorandum of understanding with “The Cultivarium”, a privately-owned micro-cultivation and research site. Negotiations towards a formal agreement were suspended in late 2021 and have since been terminated. The Company is no longer pursuing any relationship with “The Cultivarium”.

The Company wishes to announce that due to operational and staffing difficulties, it is pausing all operations related to psilocybin and research into psychedelics and novel drug development. The company will continue to look for opportunities in the space but will shift an increased focus on its current health business.

ON BEHALF OF THE BOARD OF DIRECTORS

GLOBAL HEALTH CLINICS LTD.

Jatinder Dhaliwal
Chief Executive Officer

For further information, readers are encouraged to contact Jatinder Dhaliwal, Chief Executive Officer, at 1.855.537.6272

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Information

Except for the statements of historical fact, this news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates and projections as at the date of this news release. “Forward-looking information” in this news release includes information about the intentions, plans and future actions of the Company and Wonder Scientific. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein. The Company provides forward looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.